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Purpose: Adiponectin, a biologically active substance with 
multimeric structure released by adipocytes, is considered as a 
new diagnostic/prognostic marker in the cardiovascular disease. 
The trimeric low-(LMW), the hexameric middle-(MMW) and the 
high-molecular weight (HMW) isoforms have been found in 
human peripheral circulation. It has been hypothesized that the 
HMW, that is an active form, has cardioprotective effects and its 
determination could give additional information on the role of this 
protein in cardiovascular diseases. Aim of the study was to 
determine the levels of adiponectin multimers in patients with 
dilated cardiomyopathy (DCM) and to evaluate its relationship 
with inflammatory profile and left ventricular (LV) function. 
Methods: The plasma levels of total (T) and adiponectin 
multimers were evaluated in 50 no diabetic patients with DCM 
(30 males, 38 in NYHA class I-II, 12 in NYHA class III, LVEF% 
40.6±1.4, age 57±1 yrs, BMI 26.6±0.41 kg/m2, mean±sem) and 
in 25 age- and BMI-matched healthy subjects as controls. An 
Elisa system (Alpco Diagnostics, US) was used to directly 
measure T and, after treatment with two different specific 
proteases, the HMW and the sum of MMW and HMW forms 
while the levels of the MMW and LMW were obtained by 
difference. 
Results: T adiponectin in DCM increased with respect to controls 
as a function of disease severity (3.8±0.38 mg/ml vs 5.4±0.48 in 
NYHA class I-II vs 8.0±1.9 in NYHA class III; p<0.05 NYHA III 
vs controls and NYHA I-II) and correlated with functional and 
inflammatory indices. HMW was the predominant isoform in 
plasma, accounting for 50% of T adiponectin to which was 
positively correlated (p<0.001); MMW and LMW represented 
each the 25% of total protein. HMW significantly increased in 
DCM with respect to controls (1.8±0.15 mg/ml vs 2.5±0.21 in 
NYHA class I-II vs 4.8±1.2 in NYHA class III; p<0.001 NYHA 
III vs controls and NYHA I-II) while MMW and LMW did not 
vary with respect to controls or as a function of NYHA class. 
HMW correlated negatively with LVEF% (p=0.0041), positively 
with Interleukin-6 (p<0.001) and BNP (p=0.003). No significant 
correlation with BMI was observed both for total and HMW 
adiponectin. 
Conclusions: This study demonstrates that HMW adiponectin is 
elevated in DCM patients and increases significantly as a function 
of severity. Although many studies need to identify if the HMW 
isoform is associated to cardioprotection, the significant relation 
with markers of inflammation and cardiac dysfunction, lacking for 
MMW and LMW forms, underlines the importance to investigate 
the role of HMW in this disease. 
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